Baxdrostat may combat resistant hypertension Adding baxdrostat to background antihypertensive therapy significantly reduces 24-hour ambulatory blood pressure over placebo in patients with resistant hypertension.

#MedNews - Adding #baxdrostat to background antihypertensive therapy significantly reduces 24-hour ambulatory blood pressure over placebo in patients with resistant #hypertension.

Full story 👉 buff.ly/9xOVpJw

#CardioSky

Baxdrostat Lowers BP and Albuminuria in CKD with Uncontrolled Hypertension | Docwire News Baxdrostat plus standard therapy lowered systolic blood pressure and urine albumin for patients with chronic kidney disease (CKD) and uncontrolled hypertension in the FigHTN trial.

Baxdrostat plus standard therapy lowered systolic BP and urine albumin for patients with CKD and hypertension. #kidneydisease #baxdrostat #hypertension #nephrology #nephsky docwirenews.com/post/baxdros...

Baxdrostat Shows Promise in Reducing Blood Pressure and Protecting Kidneys

A 26‑week trial in 195 CKD patients with uncontrolled hypertension found baxdrostat cut systolic pressure by 8.1 mm Hg and reduced urine albumin 55% versus placebo. Read more: getnews.me/baxdrostat-shows-promise... #baxdrostat #hypertension

Baxdrostat Shows Promise for Treating Resistant Hypertension

Baxdrostat lowered systolic pressure by 8.7 mm Hg (1 mg) and 9.8 mm Hg (2 mg) after 12 weeks in the phase 3 BaxHTN trial. Read more: getnews.me/baxdrostat-shows-promise... #baxdrostat #hypertension #phase3

New Experimental Pill, Baxdrostat, Lowers Stubborn BP In Kidney Patients - Drugs.com MedNews MONDAY, Sept. 8, 2025 A novel pill that blocks the hormone aldosterone shows promise for lowering blood pressure and potentially delaying the progression of kid

New pill #baxdrostat shows promise for treatment-resistant high blood pressure in kidney disease patients, reducing systolic BP by ~5%. Could help break the dangerous cycle where BP damages kidneys and kidney damage worsens BP. 💊🫀 www.drugs.com/news/new-exp...

Lo studio, baxdrostat riduce ipertensione non controllata o resistente (Adnkronos) - Nei pazienti con ipertensione arteriosa non controllata o resistente al trattamento che hanno ricevuto baxdrostat o placebo in aggiunta alla terapia standard, il farmaco a due dosaggi (2 mg e 1 mg) riduce in maniera statis...

TI POTREBBE INTERESSARE: Lo studio, baxdrostat riduce ipertensione non controllata o resistente ... LEGGI TUTTO #ipertensione #baxdrostat #salute #terapia #farmaci

Lo studio, baxdrostat riduce ipertensione non controllata o resistente (Adnkronos) - Nei pazienti con ipertensione arteriosa non controllata o resistente al trattamento che hanno ricevuto baxdrostat o placebo in aggiunta alla terapia standard, il farmaco a due dosaggi (2 mg e 1 mg) riduce in maniera statis...

È ACCADUTO IERI: Lo studio, baxdrostat riduce ipertensione non controllata o resistente ... LEGGI TUTTO #baxdrostat #ipertensione #salute #medicina #trattamento

Baxdrostat Pill Lowers Resistant High Blood Pressure, Study Shows

In a Phase III trial of about 800 patients, baxdrostat lowered systolic pressure by 9–10 mmHg after 12 weeks, with 40% achieving target versus under 20% on placebo. Read more: getnews.me/baxdrostat-pill-lowers-r... #baxdrostat #hypertension

Lo studio, baxdrostat riduce ipertensione non controllata o resistente (Adnkronos) - Nei pazienti con ipertensione arteriosa non controllata o resistente al trattamento che hanno ricevuto baxdrostat o placebo in aggiunta alla terapia standard, il farmaco a due dosaggi (2 mg e 1 mg) riduce in maniera statis...

Lo studio, baxdrostat riduce ipertensione non controllata o resistente ... LEGGI TUTTO #baxdrostat #ipertensione #salute #medicina #trattamento

En pacientes con hipertensión no controlada o resistente, la adición de baxdrostat a la terapia reduce la presión sistólica en posición sentada a las 12 sem #baxdrostat #hypertension www.nejm.org/doi/full/10....

Novel Antihypertensive Effective for Uncontrolled, Resistant Hypertension Aldosterone synthase inhibitor dropped seated systolic blood pressure by 9-10 mm Hg over placebo

For uncontrolled or treatment-resistant #hypertension, adding the novel aldosterone synthase inhibitor #baxdrostat improved blood pressure in the randomized BaxHTN trial.
www.medpagetoday.com/meetingcover...

ESC: 'Landmark' study backs AZ's baxdrostat for hypertension The race to market is on with Mineralys, as AstraZeneca showcases data for aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension.

The full data from #AstraZeneca's phase 3 BaxHTN trial of #baxdrostat has raised hope of an important new treatment option for people who struggle to control their #bloodpressure with current therapies.

pharmaphorum.com/news/esc-lan...

Bloeddrukverlager van AstraZeneca toont veelbelovend resultaat in laat stadium Key takeaways AstraZeneca heeft veelbelovende resultaten aangekondigd van een laat stadium onderzoek naar Baxdrostat. Dat is een onderzoeksgeneesmiddel voor de behandeling van ongecontroleerde of therapieresistente hypertensie. Patiënten die Baxdrostat kregen, hadden na 12 weken een klinisch significante verlaging van de systolische bloeddruk, vergeleken met patiënten die een placebo kregen. Het positieve resultaat versterkt het potentieel […]

Bloeddrukverlager van AstraZeneca toont veelbelovend resultaat in laat stadium #AstraZeneca #Baxdrostat #hypertensie #gezondheid #onderzoek

#baxdrostat #astazenaeca #high-blood-pressure #hypertension #late-stage-study #phase-3-trial #experimental-drug #blood-pressure-lowering #anglo-swedish-drugmaker #drugdevelopment #clinical-trial #pharmaceuticals #investment #stock-market #share-price

UBS bullish on AstraZeneca’s baxdrostat, cautious on AVANZAR Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #UBS #AstraZeneca #baxdrostat #investing #stockmarket